The goal of this project is to develop improved pharmaceutical therapies for central nervous system disease based on the relation between transmitter mechanisms and clinical function. Investigations focus on the dopamine system and closely interactive neural pathways as they relate to dementing and extrapyramidal disorders. The search for transmitter abnormalities which serve as critical determinants for Alzheimer dementia has yielded evidence casting doubt on the importance of cholinergic system abnormalities: choline acetyltransferase reductions were no greater in the parietal association cortex, where positron emission tomography shows maximum cortical dysfunction, than in the relatively spared frontal lobe. Moreover, treatment with maximum tolerated doses of a potent muscarinic agonist failed to improve cognitive performance. On the other hand, somatostatin levels were mainly reduced in the posterior parietal cortex. Neuropeptide Y, which is partially co-localized with somatostatin, was not abnormal in any cortical area. Motor fluctuations, which ultimately occur in most levodopa treated parkinsonian patients, probably do not reflect changes in peripheral clearance mechanisms but rather drug induced alterations in central pharmacodynamic factors. Both mechanical (wearable infusion pumps) and pharmaceutical (sustained release formulations) means for stabilizing plasma dopa levels are proving effective in attenuating these response fluctuations. Many of the centrally mediated pharmacological effects of peripherally administered cholecystokinin-octapeptide (CCK-8) and related peptides in rodents now appear to reflect stimulation of vagal afferents. The peripheral injection of CCK-8 analogs has, nevertheless, proven therapeutically ineffective in nonvagotomized patients. Alternate strategies for influencing central cholecystokininergic mechanisms are thus being explored, including the development of relatively lipophilic compounds to inhibit the metaloendopeptidase found responsible for initial CCK-8 degradation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Intramural Research (Z01)
Project #
1Z01NS002265-09
Application #
4696849
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1985
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Aksu, Murat; Demirci, Sevda; Bara-Jimenez, William (2007) Correlation between putative indicators of primary restless legs syndrome severity. Sleep Med 8:84-9
Lomarev, Mikhail P; Kanchana, Sulada; Bara-Jimenez, William et al. (2006) Placebo-controlled study of rTMS for the treatment of Parkinson's disease. Mov Disord 21:325-31
Fujita, Masahiro; Ichise, Masanori; Zoghbi, Sami S et al. (2006) Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol 59:174-7
Bara-Jimenez, William; Dimitrova, Tzvetelina D; Sherzai, Abdullah et al. (2006) Glutamate release inhibition ineffective in levodopa-induced motor complications. Mov Disord 21:1380-3
Leon-Sarmiento, Fidias E; Bara-Jimenez, William; Wassermann, Eric M (2005) Visual deprivation effects on human motor cortex excitability. Neurosci Lett 389:17-20
Palkovacs, Eric P; Oppenheimer, Adam J; Gladyshev, Eugene et al. (2004) Genetic evaluation of a proposed introduction: the case of the greater prairie chicken and the extinct heath hen. Mol Ecol 13:1759-69
Chase, Thomas N (2004) Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat Disord 10:305-13
Wessell, R H; Ahmed, S M; Menniti, F S et al. (2004) NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 47:184-94
Andringa, G; Lam, K Y; Chegary, M et al. (2004) Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J 18:932-4
Kase, Hiroshi; Aoyama, S; Ichimura, M et al. (2003) Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 61:S97-100

Showing the most recent 10 out of 34 publications